Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Florence T H ^a,b   Paez Ribes, Marta ^b   Xu, Ping ^b   Man, Shan ^b   Bogdanovic, Elena ^b   Thurston, Gavin ^c   Kerbel, Robert S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Institute of Clinical Evaluative Sciences   (Canada)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN 1; ANGPT1 PROTEIN, HUMAN; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ANIMAL; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; METABOLISM; MOUSE; NEOADJUVANT THERAPY; PATHOLOGY; TRIPLE NEGATIVE BREAST CANCER;

ANGIOPOIETIN-1; ANIMALS; FEMALE; HUMANS; MICE; NEOADJUVANT THERAPY; NEOPLASMS, EXPERIMENTAL; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84995400193     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36694     Document Type: Article

References (54)

1. Jayson, G. C., Kerbel, R., Ellis, L. M. & Harris, A. L. Antiangiogenic therapy in oncology: current status and future directions. Lancet 388, 518-529 (2016).
2. Kerbel, R. S. Reappraising antiangiogenic therapy for breast cancer. Breast 20, S56-S60 (2011).
3. Montero, A. J. & Vogel, C. Fighting fire with fire: rekindling the bevacizumab debate. N. Engl. J. Med. 366, 374-375 (2012).
4. Bartsch, R., Gnant, M. & Steger, G. G. Bevacizumab: no comeback in early breast cancer? Lancet Oncol. 16, 1001 1003 (2015).
5. Ebos, J. M. & Kerbel, R. S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210-221 (2011).
6. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
7. Miles, D. W. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 3239-3247 (2010).
8. Robert, N. J. et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252-1260 (2011).
9. von Minckwitz, G. et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 15, 1269-1278 (2014).
10. von Minckwitz, G. et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N. Engl. J. Med. 366, 299-309 (2012).
11. Bear, H. D. et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N. Engl. J. Med. 366, 310-320 (2012).
12. Earl, H. M. et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 16, 656-666 (2015).
13. Cameron, D. et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 14, 933-942 (2013).
14. Miller, K. et al. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. [Abstract] In: 2014 ASCO Annual Meeting. J Clin Oncol 32, 5s suppl., (abstr 500) (2014).
15. Slamon, D. J. et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. [Abstract] In: 2013 San Antonio Breast Cancer Symposium. Cancer Res 73, (abstr S1-03) (2013).
16. Bear, H. D. et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 16, 1037-1048 (2015).
17. Munoz, R. et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 66, 3386-3391 (2006).
18. Man, S., Munoz, R. & Kerbel, R. S. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev. 26, 737-747 (2007).
19. Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15, 232-239 (2009).
20. Wu, F. T. H. et al. Efficacy of co-targeting Angiopoietin-2 and the VEGF pathway in the adjuvant postsurgical setting for early breast, colorectal and renal cancers. Cancer Res, doi: 10.1158/0008-5472. CAN-16-0888 (published online, 2016 Sep 20).
21. Guerin, E., Man, S., Xu, P. & Kerbel, R. S. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 73, 2743-2748 (2013).
22. Ebos, J. M. et al. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol. Med. 6, 1561-1576 (2014).
23. Paez-Ribes, M., Man, S., Xu, P. & Kerbel, R. S. Potential Pro-invasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy. Clin. Cancer Res. 21, 5488-5498 (2015).
24. Sheridan, C. Amgen's angiopoietin blocker fails in ovarian cancer. Nat. Biotechnol. 33, 5-6 (2015).
25. Dieras, V. et al. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast 24, 182-190 (2015).
26. Huang, H., Bhat, A., Woodnutt, G. & Lappe, R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer. 10, 575-585 (2010).
27. Penault-Llorca, F. & Radosevic-Robin, N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nat. Rev. Clin. Oncol. (2016).
28. Allegra, C. J. et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol. 31, 359-364 (2013).
29. de Gramont, A. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 13, 1225-1233 (2012).
30. Haas, N. B. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387, 2008-2016 (2016).
31. Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA. 99, 11393-11398 (2002).
32. Cao, Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2, re1 (2009).
33. Ye, X. et al. VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells. Mol. Cancer. Res. 13, 1274-1282 (2015).
34. Qian, B. Z. et al. FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. J. Exp. Med. 212, 1433-1448 (2015).
35. Adler, A. P. et al. Blockade of angiopoietin-2 or Tie2 is equally effective at inhibiting tumor growth and reducing tumor vessel density in most human tumor xenograft models. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Cancer Research 74 (19 Suppl), Abstract nr 4492 (2014).
36. Srivastava, K. et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell. 26, 880-895 (2014).
37. Gamble, J. R. et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ. Res. 87, 603-607 (2000).
38. Thurston, G. et al. The anti-inflammatory actions of angiopoietin-1. EXS (94), 233-245 (2005).
39. Gavard, J., Patel, V. & Gutkind, J. S. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev. Cell. 14, 25-36 (2008).
40. Ngok, S. P. et al. VEGF and Angiopoietin-1 exert opposing effects on cell junctions by regulating the Rho GEF Syx. J. Cell Biol. 199, 1103-15 (2012).
41. Koh, G. Y. Orchestral actions of angiopoietin-1 in vascular regeneration. Trends Mol. Med. 19, 31-39 (2013).
42. Ahmad, S. A. et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res. 61, 1255-1259 (2001).
43. Stoeltzing, O. et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res. 63, 3370-3377 (2003).
44. Hawighorst, T. et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am. J. Pathol. 160, 1381-1392 (2002).
45. Tian, S., Hayes, A. J., Metheny-Barlow, L. J. & Li, L. Y. Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1. Br. J. Cancer 86, 645-651 (2002).
46. Shim, W. S. et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp. Cell Res. 279, 299-309 (2002).
47. Machein, M. R. et al. Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am. J. Pathol. 165, 1557-1570 (2004).
48. Holopainen, T. et al. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment. Cancer Res. 69, 4656-4664 (2009).
49. Daly, C. et al. Angiopoietin-2 functions as a tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 73, 108-118 (2013).
50. Huang, J. et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int. J. Oncol. 34, 79-87 (2009).
51. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15, 220-231 (2009).
52. Papadopoulos, N. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171-185 (2012).
53. Papadopoulos, K. P. et al. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clin. Cancer Res. 22, 1348-55 (2016).
54. Davis, S. et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat. Struct. Biol. 10, 38-44 (2003).